Cargando…
Intravitreal Clindamycin as First-Line Therapy for Toxoplasmic Retinochoroiditis: A Case Series
PURPOSE: To report a case series of four ocular toxoplasmosis patients who received intravitreal clindamycin as first-line treatment. MATERIALS AND METHODS: Retrospective interventional case series. RESULTS: Four (two females and two males) patients were diagnosed with active primary toxoplasmic ret...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7733341/ https://www.ncbi.nlm.nih.gov/pubmed/33324033 http://dx.doi.org/10.2147/OPTH.S288725 |
_version_ | 1783622253136576512 |
---|---|
author | Verma, Lalit Thulasidas, Mithun Gupta, Avnindra |
author_facet | Verma, Lalit Thulasidas, Mithun Gupta, Avnindra |
author_sort | Verma, Lalit |
collection | PubMed |
description | PURPOSE: To report a case series of four ocular toxoplasmosis patients who received intravitreal clindamycin as first-line treatment. MATERIALS AND METHODS: Retrospective interventional case series. RESULTS: Four (two females and two males) patients were diagnosed with active primary toxoplasmic retinochoroiditis based on their clinical presentation. All patients received intravitreal clindamycin 1mg/0.1mL as first-line therapy (two injections with 1-week interval). Oral corticosteroid 1mg/kg/day was also given in a tapering fashion over 4–6 weeks. A remarkable response was seen in all cases with improved visual acuity, sharpening of the lesion borders, and resolution of inflammation within 4–6 weeks. No recurrence or reactivation was noted until 2 years follow-up. CONCLUSION: Intravitreal clindamycin, combined with oral corticosteroids, can be considered an effective and safe first-line therapy for active toxoplasmic retinochoroiditis. It provides the patient a more convenience, safer systemic side effect profile, increased availability, and fewer follow-up visits and hematologic investigations. |
format | Online Article Text |
id | pubmed-7733341 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-77333412020-12-14 Intravitreal Clindamycin as First-Line Therapy for Toxoplasmic Retinochoroiditis: A Case Series Verma, Lalit Thulasidas, Mithun Gupta, Avnindra Clin Ophthalmol Case Series PURPOSE: To report a case series of four ocular toxoplasmosis patients who received intravitreal clindamycin as first-line treatment. MATERIALS AND METHODS: Retrospective interventional case series. RESULTS: Four (two females and two males) patients were diagnosed with active primary toxoplasmic retinochoroiditis based on their clinical presentation. All patients received intravitreal clindamycin 1mg/0.1mL as first-line therapy (two injections with 1-week interval). Oral corticosteroid 1mg/kg/day was also given in a tapering fashion over 4–6 weeks. A remarkable response was seen in all cases with improved visual acuity, sharpening of the lesion borders, and resolution of inflammation within 4–6 weeks. No recurrence or reactivation was noted until 2 years follow-up. CONCLUSION: Intravitreal clindamycin, combined with oral corticosteroids, can be considered an effective and safe first-line therapy for active toxoplasmic retinochoroiditis. It provides the patient a more convenience, safer systemic side effect profile, increased availability, and fewer follow-up visits and hematologic investigations. Dove 2020-12-07 /pmc/articles/PMC7733341/ /pubmed/33324033 http://dx.doi.org/10.2147/OPTH.S288725 Text en © 2020 Verma et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Case Series Verma, Lalit Thulasidas, Mithun Gupta, Avnindra Intravitreal Clindamycin as First-Line Therapy for Toxoplasmic Retinochoroiditis: A Case Series |
title | Intravitreal Clindamycin as First-Line Therapy for Toxoplasmic Retinochoroiditis: A Case Series |
title_full | Intravitreal Clindamycin as First-Line Therapy for Toxoplasmic Retinochoroiditis: A Case Series |
title_fullStr | Intravitreal Clindamycin as First-Line Therapy for Toxoplasmic Retinochoroiditis: A Case Series |
title_full_unstemmed | Intravitreal Clindamycin as First-Line Therapy for Toxoplasmic Retinochoroiditis: A Case Series |
title_short | Intravitreal Clindamycin as First-Line Therapy for Toxoplasmic Retinochoroiditis: A Case Series |
title_sort | intravitreal clindamycin as first-line therapy for toxoplasmic retinochoroiditis: a case series |
topic | Case Series |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7733341/ https://www.ncbi.nlm.nih.gov/pubmed/33324033 http://dx.doi.org/10.2147/OPTH.S288725 |
work_keys_str_mv | AT vermalalit intravitrealclindamycinasfirstlinetherapyfortoxoplasmicretinochoroiditisacaseseries AT thulasidasmithun intravitrealclindamycinasfirstlinetherapyfortoxoplasmicretinochoroiditisacaseseries AT guptaavnindra intravitrealclindamycinasfirstlinetherapyfortoxoplasmicretinochoroiditisacaseseries |